Please login to the form below

Not currently logged in
Email:
Password:

Veltassa

This page shows the latest Veltassa news and features for those working in and with pharma, biotech and healthcare.

Evotec and Vifor announce joint venture for kidney disease treatments

Evotec and Vifor announce joint venture for kidney disease treatments

number of treatments including Veltassa, Mircera and Velphoro.

Latest news

  • NICE says no to AZ and Vifor’s rival hyperkalaemia drugs NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

    Vifor’s Veltassa (patiromer) gained US approval in 2015 and in Europe in 2017. ... Denmark. This has given Vifor a head start overall, but Veltassa sales remain modest: it chalked up revenues of 36.8m in the first six months of 2018.

  • Real-world data finds patients feel better on Entresto, says Novartis Real-world data finds patients feel better on Entresto, says Novartis

    Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.

  • AZ gets US approval for Veltassa rival Lokelma AZ gets US approval for Veltassa rival Lokelma

    But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia. ... That left AZ playing catch-up in the market with Vifor’s Veltassa (patiromer), which was approved in the US in 2015 and got a European green light last

  • AZ finally gets EU nod for Veltassa rival Lokelma AZ finally gets EU nod for Veltassa rival Lokelma

    challenge Vifor Pharma’s Veltassa (patiromer) which was approved in the EU last year and has been sold in the US since 2015. ... For its part, Vifor has said securing payer coverage for Veltassa in the US has been a little slow, but is gaining momentum

  • Vifor wins European approval for Veltassa Vifor wins European approval for Veltassa

    The go-ahead is a significant milestone for Vifor Pharma Group - who acquired Veltassa from Relypsa - as it marks the drug’s first regulatory approval outside the US. ... Relypsa plans to submit Veltassa applications in other markets worldwide and the

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    The Vifor division, which focuses on treatments for iron deficiency, has gained a fully integrated US operation prior to the spin-out, and a complementary product in Veltassa, a potassium binder ... Veltassa was approved in late 2015 and Relypsa achieved

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics